These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

5186 related items for PubMed ID: 25824720

  • 1. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F.
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK, Atkins M.
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [Abstract] [Full Text] [Related]

  • 4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM, Freeman GJ, McDermott DF.
    Clin Ther; 2015 Apr 01; 37(4):764-82. PubMed ID: 25823918
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer.
    Dorta-Estremera S, Hegde VL, Slay RB, Sun R, Yanamandra AV, Nicholas C, Nookala S, Sierra G, Curran MA, Sastry KJ.
    J Immunother Cancer; 2019 Sep 18; 7(1):252. PubMed ID: 31533840
    [Abstract] [Full Text] [Related]

  • 8. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
    Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, Madore J, Lim SY, Velickovic R, Wongchenko M, Yan Y, Lo S, Carlino MS, Guminski A, Saw RPM, Pang A, McGuire HM, Palendira U, Thompson JF, Rizos H, Silva IPD, Batten M, Scolyer RA, Long GV, Wilmott JS.
    Cancer Cell; 2019 Feb 11; 35(2):238-255.e6. PubMed ID: 30753825
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combination of CTLA-4 and PD-1 blockers for treatment of cancer.
    Rotte A.
    J Exp Clin Cancer Res; 2019 Jun 13; 38(1):255. PubMed ID: 31196207
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs.
    Loo K, Daud AI.
    Cancer J; 2017 Jun 13; 23(1):3-9. PubMed ID: 28114249
    [Abstract] [Full Text] [Related]

  • 16. The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation.
    Blank CU.
    Curr Opin Oncol; 2014 Mar 13; 26(2):204-14. PubMed ID: 24424272
    [Abstract] [Full Text] [Related]

  • 17. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ, Gong J, Hatch MM, Nguyen V, Hughes CC, Hutchins JT, Freimark BD.
    Breast Cancer Res; 2016 May 11; 18(1):50. PubMed ID: 27169467
    [Abstract] [Full Text] [Related]

  • 18. From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
    Hussain SA, Birtle A, Crabb S, Huddart R, Small D, Summerhayes M, Jones R, Protheroe A.
    Eur Urol Oncol; 2018 Dec 11; 1(6):486-500. PubMed ID: 31158093
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
    Farina MS, Lundgren KT, Bellmunt J.
    Drugs; 2017 Jul 11; 77(10):1077-1089. PubMed ID: 28493171
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 260.